Merck Serono

Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, UK
Telephone: +44 (0)208 818 7200
Fax: +44 (0)208 818 7267
Medical Information Direct Line: +44 (0)208 818 7373
Medical Information e-mail: medinfo.uk@merckserono.net
Medical Information Fax: +44 (0)208 818 7274

Summary of Product Characteristics last updated on the eMC: 13/10/2011
SPC FemSeven Conti

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   01-Oct-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Changes are widespread throughout the document.
Updated on 05/08/2011 and displayed until 13/10/2011
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Jul-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

The following sections updated:

6.3     Shelf life

 

3 years.


10.     Date of (partial) revision of the text

 

          July 2011



Updated on 07/07/2008 and displayed until 05/08/2011
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   16-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to the name and address of the MA Holder - section 7. The following is the updated data.

7.         MARKETING AUTHORISATION HOLDER

 

Merck Serono Ltd

Bedfont Cross

Stanwell Road

Feltham

Middlesex

TW14 8NX

UK

Updated on 23/08/2004 and displayed until 07/07/2008
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 20/08/2004 and displayed until 23/08/2004
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 29/11/2002 and displayed until 20/08/2004
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 22/11/2002 and displayed until 29/11/2002
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   levonorgestrel
   estradiol hemihydrate